Sen. Bill Cassidy released an 18-page report outlining proposed reforms to streamline Food and Drug Administration processes and accelerate access to new products.
By yourNEWS Media Newsroom
Sen. Bill Cassidy (R-La.) unveiled a proposal on Feb. 17 calling for broad changes to modernize the Food and Drug Administration, arguing that regulatory bottlenecks are slowing patient and consumer access to needed products.
In an 18-page report, Cassidy—who serves as chairman of the Senate Health, Education, Labor, and Pensions Committee—wrote that while many elements of the agency function effectively, inefficiencies remain.
“While many parts of FDA work well, unnecessary bottlenecks slow patients and consumers getting the products they need,” Cassidy said in the document. “Ultimately, it should be easier to make Americans healthy by empowering them with the tools and information they need to make healthy choices and live better lives.”
One of the central recommendations calls for eliminating perceived barriers and lack of transparency in the FDA’s product review process. According to the report, some industry executives have cited inconsistent standards depending on assigned reviewers, as well as communication gaps between reviewers and senior agency leadership.
Cassidy referenced a 1997 congressional directive requiring the FDA to take the “least burdensome” regulatory approach—defined as seeking only the minimum information necessary to resolve issues while maintaining efficiency.
“To improve predictability, Congress and FDA should consider how to apply this principle to other product categories while maintaining patient safety and evidentiary standards,” he wrote. “Additionally, as Congress considers reforms, proposals should ensure there is accountability, transparency, and flexibility in the review process to meet the agency’s resources.”
The report outlines additional proposals, including reassessing clinical trial thresholds and circumstances under which companies could rely on real-world evidence rather than traditional trials. It also calls for ensuring that the FDA’s use of artificial intelligence “guards against mission-critical risks without stifling new discoveries.”
Cassidy suggested the agency should generally avoid placing clinical holds on therapies aimed at rare diseases and encouraged stronger dialogue between regulators and companies seeking product approval.
He also proposed that Congress consider legislation to limit citizen petitions to the FDA and create a streamlined pathway designed to bring cutting-edge products to market more quickly.
“While FDA has made progress, there remains enormous potential for the agency to support better and more affordable products for patients,” Cassidy concluded.
Sen. Bernie Sanders (I-Vt.), the ranking member of the Senate Health Committee, did not respond to a request for comment by publication time.
A spokesperson for the Department of Health and Human Services, the FDA’s parent agency, said officials welcome congressional engagement on modernization efforts.
“Many of the themes outlined in the white paper align with work already underway at the agency and we look forward to continued engagement with the Committee to advance these ideas in the legislative process where we share priorities,” the spokesperson said in an email.
Original article
Comments